Multidisciplinary Management of HER2+ Breast Cancer

A discussion regarding treatment advances in HER2-positive metastatic breast cancer, a heterogeneous disease.

Patient advocate Erika Rich compares initial symptoms that prompted her to seek a medical evaluation with symptoms commonly associated with HER2-positive metastatic breast cancer.

The rationale for treating Erika Rich, a patient with HER2-positive metastatic breast cancer, with docetaxel, trastuzumab, and pertuzumab.

Radiation oncologist Kamran Ahmed, MD, comments on indications for using radiation therapy to treat patients with HER2-positive de novo metastatic breast cancer.

Julia A. LaBarbera, NP, reacts to the treatment approach used for a patient with HER2-positive metastatic breast cancer, and highlights the benefits of new subcutaneous injections of trastuzumab and pertuzumab that are available.

Recommendations for deciding what information is most important to discuss with patients during initial treatment planning for HER2-positive metastatic breast cancer.

Erika Rich, a patient with HER2-positive metastatic breast cancer, explains why she opted to pursue a second opinion about her diagnosis and treatment options and proactively research her disease.

Adverse events commonly associated with chemotherapies used to treat HER2-positive metastatic breast cancer, and recommendations to help equip patients with knowledge about what to expect during their treatment journey.

Treatment recommendations for patients with HER2-positive metastatic breast cancer, like Erika Rich, upon identification of lesions in the brain.

Variables that impact decisions to treat HER2-positive breast cancer and brain metastases with radiation therapy and systemic therapy, and recommendations on using memantine following radiation therapy.

Sara A. Hurvitz, MD, and Julia A. LaBarbera, NP, of UCLA, highlight the safety and efficacy profiles of newer novel treatment options available for HER2-positive breast cancer and brain metastases.

The importance of forming partnerships with patients and understanding their preferences for therapy when establishing treatment algorithms for patients with HER2-positive metastatic breast cancer.

Various healthcare professionals join to discuss the management of a patient diagnosed with HER2-positive breast cancer and consider how to best approach newer treatment strategies through her continuum of care.

Improvements regarding the identification and management of radiation necrosis in patients with HER2-positive metastatic breast cancer.

A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.